News

October 03, 2017

Clinical trials of new drugs for the prevention of fracture are extremely expensive and typically go on for at least 3 years. Investigators have tried for decades to find a new more efficient way of conducting these trials more efficiently. The Foundation for NIH project on Bone Quality at the SFCC has discovered that hip BMD is a good surrogate for hip fracture in clinical trials.

The project has compiled data from over 100,000 participants in over 40 clinical trials. They have pooled all of this data together to create the most powerful existing tool for studying ways to make clinical trials more efficient. The project compared changes in hip BMD during the course of these trials and the change in risk of hip fracture. The scientists discovered that every 1% improvement in hip BMD in the trials accurately predicted about a 5% decrease in the risk of hip fractures. This result was presented at a recent conference held by the FDA about new guidelines for clinical trials and has been submitted to FDA to consider revising their guidelines to accept BMD as a “surrogate” to allow clinical trials to use hip BMD as an endpoint for trials to approve drug therapies for prevention of fracture. This would be a revolutionary change in approval of new treatments for osteoporosis.

 

October 03, 2017

High levels of mitochondrial DNA (mtDNA) heteroplasmy, a mixture of normal and mutated mtDNA molecules in a cell, lead to inherited mitochondrial diseases with neurological, sensory, and movement impairments. We measured mtDNA heteroplasmy at twenty disease-causing sites for associations with neurosensory and mobility function among elderly participants from a community-based study of aging.

 

May 01, 2016

Led by Dr. Steve Cummings, the SFCC has been awarded a new and exciting translational grant from NIA to test whether proteins that circulate in our blood can rejuvenate older people and reduce their risk of dementia, heart failure, frailty and even extend healthy survival.

 

May 01, 2016

In a study from MrOS from the SF Coordinating Center and led by Dr. Doug Bauer, we found that high levels of thyroid hormone that were not known to the patient or physician, indicated a 2.5 to 3.6 times greater chance of becoming frail later in life. This is a treatable condition that might lead to wasting bone and muscle.


(See abstract Virginii VS, et al. Subclinical thyroid dysfunction and frailty among older men. J Clin Endocrinol Metab 2015;100:4524-32.)